Your browser doesn't support javascript.
loading
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer.
Jhawar, Sachin R; Wang, Shang-Jui; Thandoni, Aditya; Bommareddy, Praveen K; Newman, Jenna H; Marzo, Amanda L; Kuzel, Timothy M; Gupta, Vineet; Reiser, Jochen; Daniels, Preston; Schiff, Devora; Mitchell, Darrion; LeBoeuf, Nicole R; Simmons, Christopher; Goyal, Sharad; Lasfar, Ahmed; Guevara-Patino, Jose A; Haffty, Bruce G; Kaufman, Howard L; Silk, Ann W; Zloza, Andrew; Giurini, Eileena F.
Afiliação
  • Jhawar SR; Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Wang SJ; Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • Thandoni A; Department of Orthopedic Surgery, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.
  • Bommareddy PK; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
  • Newman JH; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
  • Marzo AL; Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
  • Kuzel TM; Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
  • Gupta V; Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
  • Reiser J; Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
  • Daniels P; Department of Internal Medicine, Rush University Medical Center, Chicago, Illinois, USA.
  • Schiff D; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
  • Mitchell D; Department of Radiation Oncology, The Ohio State University Wexner Medical Center, Columbus, Ohio, USA.
  • LeBoeuf NR; Harvard Medical School, Boston, Massachusetts, USA.
  • Simmons C; Department of Dermatology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Goyal S; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.
  • Lasfar A; Department of Radiology, The George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
  • Guevara-Patino JA; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
  • Haffty BG; Department of Pharmacology and Toxicology, Ernest School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, New Jersey, USA.
  • Kaufman HL; Department of Immunology, Moffitt Cancer Center, Tampa, Florida, USA.
  • Silk AW; Rutgers Cancer Institute of New Jersey, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA.
  • Zloza A; Department of Surgery, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Giurini EF; Harvard Medical School, Boston, Massachusetts, USA andrewzloza@gmail.com ann_silk@dfci.harvard.edu.
J Immunother Cancer ; 11(7)2023 07.
Article em En | MEDLINE | ID: mdl-37433716
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma de Células Escamosas / Terapia Viral Oncolítica / Inibidores de Checkpoint Imunológico Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Cutâneas / Carcinoma de Células Escamosas / Terapia Viral Oncolítica / Inibidores de Checkpoint Imunológico Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2023 Tipo de documento: Article